Sarcoma Clinical Trials
Sarcoma
Learn More About Sarcoma
For general information on sarcoma (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| DCSZ11-101 | Sarcoma | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| ON-5001 | Sarcoma | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesion | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |
| AMT-253-01 | Sarcoma | First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti MUC18 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics (Australia) Pty Ltd | NCT05906862 | Enquire Now |